

U.S. Patent Application No. 10/203,495, filed August 9, 2002, entitled "Identification of Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function" [E-095-2000/0-US-03]; U.S. Patent Application No. 60/694,015 entitled "Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors" filed June 24, 2005 [E-095-2000/2-US-01]; U.S. Patent Application No. 60/717,589 entitled "Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors" filed September 16, 2005 [E-095-2000/3-US-01]; U.S. PCT Application entitled "A Potential Novel Therapeutic Protein Molecule of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptor Type 1" filed February 9, 2001 [E-095-2000/4-PCT-01]; European Patent Application No. 01910476.9 entitled "Identification of Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function" filed February 9, 2001 [E-095-2000/0-EP-06]; Australian Patent Application No. 2001238076 entitled "Identification of Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function" issued on February 9, 2001 [E-095-2000/0-AU-04]; and Canadian Patent Application No. 2399388 entitled "Identification of Novel Domain in the Tumor Necrosis Factor Receptor Family that Mediates Pre-ligand Receptor Assembly and Function" filed February 9, 2001, [E-095-2000/0-CA-05] to Domantis, Inc.

The prospective exclusive license territory may be worldwide and the field of use may be limited to therapeutic applications for autoimmune diseases including rheumatoid arthritis (RA) inflammatory bowel disease (IBD) and psoriasis as covered under the agreement and based upon the Patent Rights.

DATES: Only written comments and/or license applications which are received by the National Institutes of Health on or before December 5, 2006 will be considered.

ADDRESSES: Requests for copies of the patent and/or patent applications, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Mojdeh Bahar, J.D., M.A., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325,

Rockville, MD. 20852-3804; Telephone: (301) 435-2950; Facsimile: (301) 402-0220; E-mail: BAHARM@OD.NIH.GOV.

SUPPLEMENTARY INFORMATION: The invention relates to methods and compositions that are useful for novel treatment of arthritis and other autoimmune diseases. This technology discloses the identification of a functional domain, Pre-ligand Assembly Domain (PLAD), an essential part in signaling involving receptors of the Tumor Necrosis Factor superfamily and its use in ameliorating rheumatoid arthritis (RA). PLAD is essential for signaling involving TNFR including TNFR-1 (p60), TNFR-2 (p80), Fas, TRAIL-R, LTR, CD40, CD30, CD27, HVEM, OX40 and DR4 and can be isolated as functional polypeptides which can be useful in inhibiting the first step in TNFR mediated signaling, ligand-independent assembly of members of the TNFR superfamily. The ability to inhibit TNFR signaling suggests that these PLAD polypeptides may be useful in development of new therapeutic molecules or as therapeutic molecules themselves used for modulation of immune responses, apoptosis, and inflammation. The inventors have discovered compounds that interfere with PLAD and can block the effects of TNF- α .

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: September 28, 2006.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E6-16526 Filed 10-5-06; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Fogarty International Center (FIC) 2007-2011 Strategic Plan

AGENCY: John E. Fogarty International Center (FIC), National Institutes of Health. (NIH), Department of Health and Human Services (DHHS).

ACTION: Notice with request for comments.

SUMMARY: The FIC is initiating a strategic planning process to culminate in the FIC Strategic Plan 2007-2011. To anticipate and set priorities for global health research and research training, FIC requests input from scientists, the general public, and interested parties. The goal of this strategic planning process is to identify current and future needs and directions for global health research. The existing FIC strategic plan can be viewed at <http://www.fic.nih.gov/about/plan/StrategicPlan.pdf>.

DATES: In order to ensure full consideration, responses must be submitted by November 15, 2006.

ADDRESSES: Interested persons and organizations should submit their responses to Strategic Plan, Fogarty International Center, National Institutes of Health, 16 Center Drive, Building 16, MSC 6705, Bethesda, MD 20892-6705, telephone 301-594-7857, Fax 301-496-8496, E-mail: FICStratPlan@nih.gov. Comments may be submitted electronically via the Strategic Planning Web site located at <http://nihfictest.cit.nih.gov/StratPlan/index.htm>. Comments may also be submitted by mail or fax to the address above.

SUPPLEMENTARY INFORMATION:

Background

The Fogarty International Center (FIC) works to enhance global health by promoting and supporting health research and research training worldwide. The Center uses a variety of international research and research training grants and fellowships to build research capacity and human capital in developing countries and foster partnerships between U.S. scientists and their foreign counterparts. The FIC is currently developing a new strategic plan to guide Center activities for the next 5 years mindful of the need to set research and research training priorities. We welcome outside participation in the process.

Request for Comments: To ensure the continued relevance of its Strategic

Plan, the FIC seeks input on the following questions:

(A) What do you see as the major emerging opportunities and challenges in basic, applied and translational global health research?

(B) What are the specific gaps or barriers in current global health research that should be addressed by FIC in the future?

(C) What strategies can FIC pursue to enhance the ability of research institutions in low and middle income countries to become more sustainable research enterprises?

(D) How can we enhance our collaborations with the foreign policy community to facilitate global health research and research training?

(E) What are the outreach and communications opportunities in global health research that should be addressed by FIC?

(F) What are the key health research training experiences that FIC should support to attract and prepare the next generation of U.S. scientists for careers in global health research?

(G) For current and former FIC trainees or others involved in FIC research training awards:

(i) How has FIC helped to advance your career in the past and helped to build health research capacity at your institution?

(ii) Do you have any suggestions for future FIC directions with respect to health research training and capacity building?

(H) Other comments.

FOR FURTHER INFORMATION CONTACT: To obtain more information on the proposed project or to obtain a copy of the data collection plans and instruments, please contact: Dr. Linda Kupfer, Fogarty International Center, National Institutes of Health, 16 Center Drive, Building 16, Bethesda, MD 20892-6705, or call 301-496-3288 (this is not a toll-free number), or e-mail your request, including your address to: KupferL@mail.nih.gov.

Dated: October 2, 2006.

Richard Miller,

Executive Officer, FIC, National Institutes of Health.

[FR Doc. E6-16527 Filed 10-5-06; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-5045-N-40]

Federal Property Suitable as Facilities To Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

DATES: *Effective Date:* October 6, 2006.

FOR FURTHER INFORMATION CONTACT:

Kathy Ezzell, Department of Housing and Urban Development, Room 7262, 451 Seventh Street, SW., Washington, DC 20410; telephone (202) 708-1234; TTY number for the hearing- and speech-impaired (202) 708-2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588

SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in *National Coalition for the Homeless v. Veterans Administration*, No. 88-2503-OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless. Today's Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week.

Dated: September 28, 2006.

Mark R. Johnston,

Acting Deputy Assistant Secretary for Special Needs.

[FR Doc. 06-8465 Filed 10-5-06; 8:45 am]

BILLING CODE 4210-67-M

DEPARTMENT OF THE INTERIOR

Bureau of Indian Affairs

Final Environmental Impact Statement for the Elk Valley Rancheria's Proposed 203.5 Acre Martin Ranch Fee-to-Trust Transfer and Casino/Resort Project, Del Norte County, CA

AGENCY: Bureau of Indian Affairs, Interior.

ACTION: Notice.

SUMMARY: This notice advises the public that the Bureau of Indian Affairs (BIA), in cooperation with the Elk Valley

Rancheria (tribe), City of Crescent City, U.S. Army Corps of Engineers, U.S. Fish and Wildlife Service, California Department of Fish and Game, and U.S. Environmental Protection Agency (EPA), intends to file a final Environmental Impact Statement (FEIS) with the EPA for the proposed approval of a 203.5-acre fee-to-trust transfer and casino/resort complex in Del Norte County, California, and that the FEIS is now available to the public. The purpose of the proposed action is to help provide for the economic development of the tribe.

DATES: The Record of Decision on the proposed action will be issued on or after November 7, 2006. Any comments on the FEIS must arrive by November 6, 2006.

ADDRESSES: You may mail or hand carry written comments to Clay Gregory, Regional Director, Bureau of Indian Affairs, Pacific Region, 2800 Cottage Way, Room W-2820, Sacramento, California 95825. Please include your name, return address and the caption, "FEIS Comments, Elk Valley Rancheria, Martin Ranch, Fee to Trust Casino/Resort Project," on the first page of your written comments.

The FEIS will be available for review at the Del Norte County Library, located at 190 Price Mall, Crescent City, California 95531. General information for the Del Norte County Library District can be obtained by calling (707) 464-9793.

If you would like to obtain a copy of the FEIS, please provide your name and address in writing or by voicemail to John Rydzik, Chief of the Division of Environmental, Cultural Resource Management and Safety, at the BIA address above or at the telephone number provided below.

FOR FURTHER INFORMATION CONTACT: John Rydzik, (916) 978-6042.

SUPPLEMENTARY INFORMATION: The tribe has asked the BIA to take 203.5 acres of land into trust on behalf of the tribe, on which the tribe proposes to develop a casino, hotel, conference center and parking facility. The project site, known locally as the Martin Ranch, is located one mile southeast of the City of Crescent City, California, adjacent to Highway 101 and Humboldt Road. The site is currently undeveloped, with the exception of a single-family residence, associated outbuildings, and barn. Regional access to the project site would be via Highway 101. Humboldt Road would provide primary local access to the casino.

Project alternatives considered in the FEIS include: (1) The preferred casino, hotel, conference center, and parking